Stay updated on ABP 798 vs. Rituximab in RA Clinical Trial
Sign up to get notified when there's something new on the ABP 798 vs. Rituximab in RA Clinical Trial page.

Latest updates to the ABP 798 vs. Rituximab in RA Clinical Trial page
- Check2 days agoChange DetectedThe web page has been updated from version 2.16.2 to version 2.16.3.SummaryDifference0.0%
- Check10 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.0%
- Check17 days agoChange DetectedThe web page has been updated to reflect the upcoming modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, along with an invitation for API users to provide input. Additionally, the revision number has been updated from v2.16.0 to v2.16.1.SummaryDifference0.8%
- Check24 days agoChange DetectedThe web page has been updated to version 2.16.0, replacing the previous version 2.15.2.SummaryDifference0.1%
- Check45 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.0%
- Check60 days agoChange DetectedThe page has undergone significant content removal, including detailed descriptions of a clinical trial for the investigational medicine ABP 798, which compared its effects to the licensed medicine rituximab for treating rheumatoid arthritis. Additionally, the revision number has been updated from v2.14.4 to v2.15.0.SummaryDifference8%
Stay in the know with updates to ABP 798 vs. Rituximab in RA Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ABP 798 vs. Rituximab in RA Clinical Trial page.